Engineering small‐molecule analogues of altiratinib via CREB‐regulated transcription co‐activator 3‐target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases

• Jeong Hyeon Lee,
• Hongchan An,
• HyeJi Kwon,
• Su‐Jeong Lee,
• Young Hye Park,
• Ji Sun Hwang,
• Min Young Kim,
• Hayoung Hwang,
• Jeong Yoon Kim,
• Seung Jin Lee,
• Sung Eun Chang,
• Youngsup Song

Affiliations

Jeong Hyeon Lee

Department of DermatologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea

Hongchan An

College of Pharmacy and Institute of Pharmaceutical SciencesCHA UniversityPocheon South Korea

HyeJi Kwon

Department of Brain ScienceBrain Korea 21 projectUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea

Su‐Jeong Lee

New Drug Development Center (NDDC)Daegu‐Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguSouth Korea

Young Hye Park

New Drug Development Center (NDDC)Daegu‐Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguSouth Korea

Ji Sun Hwang

New Drug Development Center (NDDC)Daegu‐Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguSouth Korea

Min Young Kim

New Drug Development Center (NDDC)Daegu‐Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguSouth Korea

Hayoung Hwang

New Drug Development Center (NDDC)Daegu‐Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguSouth Korea

Jeong Yoon Kim

Department of Brain ScienceBrain Korea 21 projectUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea

Seung Jin Lee

Department of Brain ScienceBrain Korea 21 projectUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea

Sung Eun Chang

Department of DermatologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea

Youngsup Song

Department of Brain ScienceBrain Korea 21 projectUniversity of Ulsan College of Medicine, Asan Medical CenterSeoul South Korea